Reports Q1 revenue $289.46M, consensus $280.26M. “The start to fiscal 2025 was largely consistent with our expectations, as a high-level of execution by the Bio-Techne (TECH) team drove continued momentum across our Diagnostics & Spatial Biology segment,” said Kim Kelderman, president and CEO of Bio-Techne. “This was augmented by strong results in our cell and gene therapy business, including robust growth in our GMP reagent portfolio. The strength in cell and gene therapy, combined with favorable year-to-date funding dynamics, gives us increased confidence in the forthcoming recovery in our biotech end market.”
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio